Terfenadine, a second histamine H1 receptor antagonist has previously been reported for its apoptosis-inducing properties against a variety of cancer cells [90–92], including human melanoma cells [93, 94] and more recently prostate cancer cells [95]. This evidence concerns the gene HRH1 and Familial prostate cancer.